The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Toyin, even you must realise that nothing has been sold by Croda so little chance of any percentage. It's a long way off, if ever.
The possible acquisition of private company that has branded topical products for common dermatological conditions such as psoriasis and eczema rather suggests that AxisBiotix provides little or no symptom relief. Any port in a storm???
Time for a new CEO. This one is just full of BS
Clio,
Check your google settings. Select region, UK and you should find it top ad on first screen. I will also reduce the proliferation of US websites when you do any search if you specify UK as the region
Clio,
Your posts tend to be more balanced and objective than most on this board and so was somewhat surprised by, 'The majority of us realise that Stuart Ashman’s vision, creative ability and business acumen are phenomenal' posted 20:22
From where I'm sitting SA has done nothing to justify that view. What exactly, in your opinion, has he delivered to justify? SP probably answers that one!
'In SA we trust' and other such drivel from the ramper's corner. So far we have seen nothing to justify that note of support.
Let's see what the Pied Piper of Manchester uncovers of real value, if anything, on Friday.
What's happened to the ramping society this morning? Can't blame them for keeping quiet given this morning's dismal update.
They lead with their oral programme which, today, is nothing more than a deposit in a petri dish and, should it prove to be efficacious, is years away from productisation. Licensing to one of the mysterious, 'multinationals' may help but short even mid term....no! Probably intended more as a distraction from the other points covered.
AxisBiotix sales nothing short of pathetic. Given a single pack last year cost £48, doesn't take a genius to work out that they haven't sold many. As for the high subscription retention rate that has been constantly ramped but with no base numbers for estimating actual sales, unfortunately 85% of bugger all is...not much!!
Croda, our saviour surely, but not much on them. What has happened to Sederma's handful of privileged customers with early access to the lysate? Surely not far from product launch? What's happened to the additional benefits of the lysate discovered by Sederma during their testing? Not much on that either. OK, SBTX most likely under NDA, but if that's the case not worth mentioning that Sederma are awaiting outcome of marketing activities with the rest of their client base.
We got the usual line of, 'talking to multinationals', straight out of the corporate playbook and utterly meaningless until some real data is released about those dialogues. SA has always been described as, 'in SA we trust'. Never met the guy so can't/won't comment but the update looks like a typical AIM RNS spindoc.
A very disappointing update which, in reality, told us nothing of any value from a business development standpoint.
"I'm building a company not a share price"!
How often have we heard that arrogant statement from SOH. Not doing very well with either is he, given the dismal RNS yesterday and the plummeting SP.
Some things that need to happen and quickly:
1. A substantial SweetBiotix deal with a household name in the USA and/or Europe. And I mean a genuine household name such as a Nestle, Unilever, Hershey's and/or a General Mills!
2. Best, a new CEO, or, if not, a serious dilution in the current incumbent's arrogance. The BoD need to flex their muscles, if any! When did you last hear anything from the Chairman?
3. A heavyweight II taking a stake in Opti sufficient to influence strategy
2. won't happen and isn'y happening with regards to the BoD. 3. unlikely as Opti is SOH's baby and he will not tolerate any reduction in control that will come from selling some of his holding.
Something needs to happen to stop the bs. Investors might not like bad news but what I'm confident of is that none of us have any tolerance for the constant bs and spin. Deals done that don't deliver; big deals about to be done that never happen. How many times have we been updated on the current moving goalposts.....SweetBiotix?
This is a company with some fabulous technology which has had more than enough time to deliver spectacular results but nada!
The claim that you were responsible for the OPTI sp rise after your negative commentary on the Two Oiks podcast will do for starters.
Furthermore, as you are no longer an OPTI shareholder perhaps you could clear off and take your over inflated ego and smug, self-righteousness with you!
Oleric,
This SP drop is no laughing matter but really appreciate your effort to inject a little humour into this BB. Could certainly do with it. Not sure the majority of regulars (read rampers) will appreciate it though!!
The sentimental outpouring of support for SA over the weekend does not appear to be endorsed by the market this morning......oh dear!!
Phat,
...and how do you know, 'everything else is running on schedule' You haven't a clue!
...and, 'we can see the marketing campaigns really working' Where's your evidence? The only way you can judge that is through improved sales figures. No evidence of that yet.
Fact is, the big SBTX hit last year was going to be AxisBiotix. A dismal flop despite best efforts of the ramping community to brush over. This year it would appear AxisBiotix is being parked in preference for other product opportunities that the rampers can pump to their little hearts content because there is no information to challenge their spurious claims.
As for the, 'in SA we trust' camp. Sorry to disappoint you and others, but trusting in SA is not going to deliver results as we have already seen. Start talking about trusting him when, and only when, he delivers tangible growth results and we see that reflected in the SP.
Good luck Phat with your 'top ups'!!
They may well work for the NHS but in no way does that stop them being a bunch of self-righteous, attention seekers with no interest in anything other than headlines that might support their campaigning. Also let's not forget that NHS doctors don't spend time with patients anymore so have plenty of time producing stuff like EveryDoctor!
Why should Stephen Hammond do anything for OPTI without some form of compensation? That's how the world works or used to work!!
Unfortunately, thanks to social media, we have to put up with noise like this and hope that it doesn't have a negative impact on investors, both PIs and IIs, and potential clients.
Chest cleared.....for now!!!
Phat,
15 - 40% of what? I can't see any revenue forecasts or is that the ramper's crystal ball working overtime? Also yesterday your miss was 25 - 40%. What's that crystal ball going to show tomorrow? Could be a typo I suppose!
Toyin,
Thanks for detailed response.
With regards to no budget for press coverage, probably not relevant as media would have had an interest if results were proven and newsworthy. It would have been free! Not convinced results are proven yet. As far as I am aware there is no published data around AxisBiotix sales increases so until such time as we see an RNS from SBTX with that data it is not fact!
With regards to Croda, I'm sure the lysate is being scrutinised by their clients and no doubt in the goodness of time we will see the proverbial puff of white smoke as and when a client decides to use. However, my point is more why Sederma is still investing significant time and funds into matrixyl.
For what its worth, I've been invested in SBTX since IPO and am still in profit. I have faith in SA but my confidence is nowhere near as strong. Suspect that is no different from most others at this moment
Oleric,
Excellent posts - balanced and objective. Reaction from the rampers yesterday was not surprising as they cannot/will not tolerate any comments, no matter how accurate, that contain anything that might be deemed negative.
The launch of AxisBiotix was a damp squib and, so far, there has been nothing by way of factual evidence, for example meaningful sales data, to change that position. I am reasonably confident that we will receive more positive news later in the year but as for it being some sort of universal panacea for psoriasis and any other skin ailment you care to think about as suggested by the ramping crew then....NO!
If AxisBiotix was as beneficial as has been frequently suggested then it would have been plastered over the UK media....nada. Not even a token squeak in the Daily Mail that I'm aware of!!
AxisBiotix was last year's big story and, conveniently, we now have the Croda initiative to take our attention. I would urge all/any investor to check-out Croda's investors presentation 29th March 'Accelerating growth in Consumer Care'. Some time talking about Sederma's continued research and investment into matrixyl. It's significant . Yet no mention of the SBTX lysate which has been bigged up as the next great skin care treatment, certainly by the ramping crew, and supposedly due for launch later this year. A missed opportunity or what??